Dr. Bhatia joined our board in 2015. She currently serves as the John J. and Dorothy Wilson Professor of Engineering at the Massachusetts Institute of Technology (MIT), Director of the Marble Center for Cancer Nanomedicine, and an investigator for the Howard Hughes Medical Institute. She also holds appointments at the Koch Institute for Integrative Cancer Research, the Broad Institute, the Wyss Institute and Brigham and Women’s Hospital. In 2018, Dr. Bhatia was on sabbatical from MIT while she served as a co-founder of Glympse Bio, a private company focused on developing in vivo sensing technology dedicated to disease monitoring. Prior to joining MIT in 2005, Dr. Bhatia was a professor of bioengineering and medicine at the University of California at San Diego from 1998 through 2005. Dr. Bhatia holds an Sc.B. in biomedical engineering from Brown University, an S.M. in mechanical engineering and a Ph.D. in biomedical engineering from MIT, and an M.D. from Harvard Medical School. Dr. Bhatia was the 25th person in history to be an elected member of all three U.S. National Academies: the National Academy of Science, the National Academy of Medicine and the National Academy of Engineering. She has been honored with the Lemelson-MIT Prize, the Heinz Medal and the Othmer Gold Medal for groundbreaking inventions and advocacy for women in STEM fields.

Charlie has deep corporate finance and health care experience, including more than a decade in public and private company Chief Financial Officer roles. He joined Vertex in 2019 and oversees the accounting, finance, internal audit, investor relations, business development transactions and alliance management, and global security and facilities functions. 

He holds a B.S. in accounting from Boston College and an M.B.A. from Harvard Business School. Before joining the Vertex leadership team, he held leadership roles at Ortho Clinical Diagnostics (a Carlyle Group portfolio company), Bruker Corporation, Progress Software Corporation and Millipore Corporation. 

Nia has extensive experience in global regulatory affairs in the pharmaceutical industry. She joined Vertex in 2017, and she provides global regulatory leadership and manages all regulatory interactions and quality assurance involving the research and development, manufacturing and commercialization of our medicines. In addition to creating and executing the company’s global regulatory strategy, Nia also manages a worldwide team of regulatory professionals. 

She graduated with a B.S. in biology from Temple University and a Ph.D. in cell and molecular biology from the University of Vermont. Before joining Vertex, she held positions of increasing responsibility at pharmaceutical companies such as Sanofi, Stemnion, Pfizer and Wyeth.  

In addition to her responsibilities at Vertex, Nia serves on the board of directors of the International Institute of New England. In 2021, she was named to Fierce Pharma’s list of the Fiercest Women in the Life Sciences. 

Amit joined Vertex in 2007 and has dedicated more than 15 years of his career to various leadership positions across Vertex, including establishing our first international commercial operations in 2010. Amit oversees Vertex’s government affairs and public policy, patient and community engagement, medical affairs and external affairs functions. He leads Vertex’s efforts to build and strengthen relationships with patient, medical and community partners and external stakeholders globally.

He earned a B.S. from Carnegie Mellon University and a J.D. from Emory University. Prior to Vertex he held roles with the Biotechnology Innovation Organization (BIO), the U.S. Food and Drug Administration and the U.S. House of Representatives. He currently serves on the board of directors of Eiger BioPharmaceuticals. 

Carmen has deep experience leading global clinical development programs across all phases of development and across multiple diseases and therapeutic modalities. She joined Vertex in 2019 and is responsible for developing and driving the execution of our clinical development programs, including clinical development, medical affairs, drug safety, global clinical operations and biometrics. 

She graduated with her medical degree from McGill University, where she also completed a residency in internal medicine and served as Chief Resident. She completed a combined fellowship in pulmonary and critical care medicine at Brigham and Women’s Hospital and Beth Israel Deaconess Medical Center. 

Carmen serves as a member of the Clinical Advisory Committee at Akili Interactive. Previously she was the industry representative to the U.S. Food and Drug Administration’s Risk Communication Advisory Committee and was a member of PhRMA’s Clinical and Preclinical Development Committee. 

Stuart joined Vertex in September 2012. As Vertex’s Executive Vice President and Chief Operating Officer, he oversees Vertex’s global commercial team, which includes activities that support the approved use of Vertex’s marketed medicines around the world. He also leads the program and portfolio management, human resources and corporate communications functions.

He graduated with a degree in pharmacology and physiology from the University of Leeds in the United Kingdom, and prior to Vertex, he held multiple leadership roles at Amgen and GlaxoSmithKline (GSK) plc.  

Stuart serves on the board of directors for Rhythm Pharmaceuticals and on the Executive Committee and Health Section Governing Board for the Biotechnology Innovation Organization (BIO). He is also co-chair of the BIO Standing Committee on Access & Value.

David’s passion for human biology and therapeutic innovation has driven his 40-year career as a physician scientist. He joined Vertex in 2015 and leads internal research and external innovation, corporate data strategy, technology and data sciences. With the goal of discovering transformative medicines for the treatment of serious diseases, he developed and implemented our research strategy and is responsible for shaping the research pipeline. He serves as the executive sponsor for Vertex University. Before joining as Vertex’s Chief Scientific Officer, he served on the company’s board of directors from 2012 to 2014. 

Prior to Vertex, David was a Founding Core Member, Deputy Director and Chief Academic Officer at the Broad Institute of Harvard and the Massachusetts Institute of Technology (MIT). He was Professor of Genetics and Medicine at Harvard Medical School, Adjunct Professor of Biology at MIT and a physician at the Massachusetts General Hospital (MGH). He earned his bachelor’s degree in life sciences from MIT, his M.D. and Ph.D. in genetics from Harvard Medical School and completed his clinical training at MGH. He is a Fellow of the American Academy of Arts and Sciences and an elected member of the National Academy of Medicine. 

David is actively involved in the medical and scientific community, including as chair of the Scientific Advisory Board of the Wellcome Sanger Institute, the MGH Research Institute Advisory Council, the Science Review Board of the Howard Hughes Medical Institute, and the board of directors of the Boston Museum of Science. He continues to teach students as a senior lecturer in genetics and medicine at MGH and Harvard.  

He has received numerous awards including the Curt Stern Award of the American Society of Human Genetics and the Outstanding Scientific Research Award of the American Diabetes Association. The Obama White House named him a Champion of Change for his leadership in creating and leading the Global Alliance for Genomics and Health. In 2021, he was named one of the Top 20 Most Influential R&D Executives in drug development by Endpoints News.

Dr. Leiden is a physician and scientist who has dedicated his career to improving the lives of people with serious diseases. He currently serves as our Executive Chairman and was our Chief Executive Officer and President from 2012 through March 2020. He has been a member of our board of directors since July 2009, chairman of the board of directors since May 2012, and served as lead independent director from October 2010 through December 2011. Under his leadership, Vertex delivered the first and only medicines to treat the underlying cause of cystic fibrosis for patients with certain forms of the disease including KALYDECO^®, ORKAMBI^® and TRIKAFTA^®.

As CEO, Dr. Leiden also built a robust pipeline of drug candidates in specialty markets, including pain, sickle cell disease and type 1 diabetes, with a particular focus on therapies that cure or modify the course of disease. In 2015, he established a collaboration with CRISPR Therapeutics to develop a clinical program which is currently investigating the first potentially curative human gene-editing therapy for sickle cell disease and beta thalassemia. In 2019, he led the Vertex acquisition of Semma Therapeutics to develop a clinical program to investigate what may be the first potentially curative stem cell-based therapy for type 1 diabetes.

During his tenure as CEO Dr. Leiden established a signature program at Vertex to enhance STEAM education among students in Vertex’s local communities, including an on-site Learning Lab, mentorship programs, internships and college scholarships. In 2017, Vertex announced a sustained corporate giving commitment of $500 million over the next 10 years, of which $50 million is focused on STEAM education.

Prior to joining Vertex, Dr. Leiden was a managing director at Clarus Ventures, a life sciences venture capital firm, from 2006 through January 2012. Dr. Leiden was President, Chief Operating Officer and Chief Scientific Officer of Abbott Laboratories, Pharmaceuticals Products Group, and a member of the board of directors of Abbott Laboratories from 2000 to 2006. At Abbott he led the development and commercialization of HUMIRA^®. From 1987 to 2000, Dr. Leiden held several academic appointments, including the Rawson Professor of Medicine and Pathology and Chief of Cardiology and Director of the Cardiovascular Research Institute at the University of Chicago, the Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health, and Professor of Medicine at Harvard Medical School. He is an elected member of both the American Academy of Arts and Sciences and the National Academy of Medicine.

Dr. Leiden serves as a director of Massachusetts Mutual Life Insurance Company and as chairman of Odyssey Therapeutics, a privately held company developing novel medicines for the treatment of cancer and autoimmune diseases, and Casana Health, a privately held home-health monitoring company. He is also a member of the MIT CEO Advisory Board, a member of the Harvard Medical School Board of Fellows, a director of the Massachusetts Competitive Partnership (MACP), and a strategic advisor for J.P. Morgan’s Life Sciences Private Capital.

Dr. Leiden was previously a director and the non-executive vice chairman of the board of Shire plc, a specialty biopharmaceutical company, from 2006 to January 2012, a director of Quest Diagnostics, a medical diagnostics company, from December 2014 to May 2019, and chairman of the Massachusetts Competitive Partnership (MACP) from January 2020 to December 2022. Dr. Leiden received his M.D., Ph.D. and B.A. degrees from the University of Chicago.

Reshma is the Chief Executive Officer and President at Vertex, a Fortune 500, global biotechnology company. She trained in internal medicine and nephrology before entering the biopharmaceutical industry, where she has dedicated her career to discovering and developing new medicines. She joined Vertex in 2017, served as Chief Medical Officer and Executive Vice President of Global Medicines Development and Medical Affairs and became CEO in 2020.

In this period, Vertex expanded its success in treating cystic fibrosis (CF), with medicines that hold the potential to treat patients as young as one-month old and as many as 90 percent of all patients diagnosed with CF. Building on that work, Vertex’s R&D pipeline has treatments in multiple disease areas and across multiple modalities including small molecule, mRNA, cell and gene therapies. Since 2017, Vertex has doubled its employee base and the number of medicines it offers, significantly expanded its clinical-stage pipeline, and augmented its footprint in Boston’s Seaport and around the world. All the while, Vertex continues to foster its strong culture of belonging, diversity and equity. Continuing the tradition of excellence in the workplace, Vertex has consistently been recognized as a best place to work, including by Science magazine, The Boston Globe, Newsweek and Fortune.

Reshma is committed to supporting biomedical innovation, the next generation of scientists, and her community. She serves on Year Up's national board of directors, the Biomedical Science Careers Program’s board of directors, the Massachusetts General Hospital board of trustees and the Boston University Chobanian & Avedisian School of Medicine Dean’s Advisory Board. She also serves on the Ginkgo Bioworks board of directors, where she chairs the Nominating and Corporate Governance Committee.

She completed her internship and residency in internal medicine at the Massachusetts General Hospital, and her fellowship in nephrology at the Massachusetts General Hospital and Brigham and Women’s Hospital combined program. She received her medical degree, with honors, from the seven-year medicine program at the Boston University Chobanian & Avedisian School of Medicine, and is a Fellow of the American Society of Nephrology. She is an alumna of the Harvard Business School, having completed the General Management Program.  

Reshma has received a number of distinguished honors and awards for her leadership and contributions to science and innovation, including the Harvard Business School Alumni Achievement Award, the Distinguished Alumni Award from the Boston University School of Medicine, the International Institute of New England Golden Door Award, the New England Council New Englander of the Year award, and the Asian American Business Development Center Pinnacle Award. She has been named one of Fortune's Most Powerful Women, one of Boston Business Journal's “Power 50,” one of Boston magazine's most influential Bostonians, and one of Business Insider's “10 People Transforming Healthcare.”